PROTEOblood : Development of new therapies against two subtypes of lymphoma and leukaemia.
Significant progress has recently been made in the diagnosis and selective treatment of certain blood cancers. However, most of these malignancies remain incurable. There is considerable evidence to suggest a relationship between imbalances in protein homeostasis and the development of certain subtypes of leukaemia and lymphoma. The study of this phenomenon requires highly specialised knowledge, and represents a significant economic and knowledge challenge that individual institutions cannot effectively address. The objective of PROTEOblood is to optimise, share and exploit a set of state-of-the-art technologies and resources through the coordination of academic and private partners from different POCTEFA territories, for the study of protein homeostasis in two prevalent subtypes of leukaemia and lymphoma. PROTEOblood will generate innovative technologies and tools transferable to the development of personalised drugs against these diseases. We will establish a collection of patient-derived study models (organoids and xenografts) capable of recreating the tumour microenvironment ex vivo. Cutting-edge proteomic approaches, combined with systems biology analysis and small molecule design, will enable the comprehensive characterisation of proteinopathies and the development of safe and effective therapies that will be validated in the organoid and xenograft collections. PROTEOblood will thus promote technological development, cross-border cooperation and knowledge exchange, facilitating the optimisation of existing infrastructures and resources. As the PROTEOblood partners have complementary capabilities illustrated by previous co-authored publications, patents and licenses, this project will undoubtedly increase the competitiveness and internationalisation of the POCTEFA regions.
CRCT partner: Jean Emmanuel Sarry
For more information: https://www.poctefa.eu/fr/listes-de-projets/detail-du-projet/?IdProyecto=919a3a25-ec03-4fed-9528-1e6d883683ff
Start date: June 2020
End date: May 2022
The project has been 65% co-financed by the European Regional Development Fund (ERDF) within the framework of the Interreg V-A Spain-France-Andorra programme (POCTEFA 2014-2020). https://www.poctefa.eu/fr/
